Sales of GLP-1 receptor agonists and SGLT-2 Inhibitors exceed $8 billion in across the seven major markets in 2017

During 2017, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter -2 (SGLT-2) inhibitors marketed across the seven major markets (USA, 5EU [France, Italy, Germany, Spain, UK], and Japan: 7MM) brought in more than $8 billion in combined sales

According to analytics company GlobalData, both T2D drug classes continue to gain substantial market share through the glycemic and non-glycemic benefits (eg, CV benefits, weight and/or blood pressure reductions) they confer.

Jesus Cuaron, managing healthcare analyst at GlobalData, commented: ‘‘Across the 7MM, there are currently fourteen approved GLP-1 receptor agonists and SGLT-2 inhibitors collectively (not including combination varieties). The timeline of approved GLP-1 receptor agonists and SGLT-2 inhibitors in the 7MM, confirms that Novo Nordisk’s (NOV: N) Ozempic (semaglutide) and Merck & Co (NYSE: MRK) and Pfizer’s Steglatro (ertugliflozin) received the most recent regulatory approvals in 2017. ‘’